CPA
VTYX

Capital Performance Advisors’s Ventyx Biosciences VTYX Stock Holding History

Capital Performance Advisors’s Portfolio VTYX Stock Details VTYX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-173
Closed -$377 – 2652
2024
Q3 		$377 Buy
+173
New +$398 ﹤0.01% 2377

Other funds holding VTYX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Capital Performance Advisors's VTYX Position: Q4 2024 in Review

Capital Performance Advisors sold out of Ventyx Biosciences (VTYX) in Q4 2024, closing a stake of 173 shares — an estimated $377 sold.

Capital Performance Advisors first reported a position in VTYX in Q3 2024 and held it in 1 quarter. The position peaked at $377 in Q3 2024. 124 funds tracked by Wall St. Rank hold VTYX as of Q4 2024.

  • Capital Performance Advisors reported no remaining Ventyx Biosciences position as of Q4 2024 after selling out during the quarter.
  • Capital Performance Advisors sold 173 Ventyx Biosciences shares in Q4 2024, an estimated $377.
  • Capital Performance Advisors first reported a position in Ventyx Biosciences in Q3 2024 and held it in 1 quarter.
  • Capital Performance Advisors's Ventyx Biosciences position peaked at $377 in Q3 2024.
  • 124 funds tracked by Wall St. Rank held Ventyx Biosciences as of Q4 2024.

Based on Capital Performance Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.